2nd Targeted Intracellular Delivery Summit

Accelerate Your Insight of Mechanisms of Action, Cellular Pathways and Endosomal Escape to Gain Access to Tumor and Cell-Specific Targets

Step into the 2nd Targeted Intracellular Delivery Summit, a thrilling exploration of cutting-edge advancements in drug delivery. This year, we redefine possibilities, venturing beyond traditional boundaries with a focus on cellular biology and intracellular mechanisms.

Optimize drug delivery, overcome endosomal challenges, and expand therapies beyond the liver with in-depth case studies and a Pre-Conference Workshop Day. Gain insights into targeted cell interventions for cancer and autoimmune diseases, re-thinking innovative delivery platforms and strategies for cargo delivery into novel targets.

Engage in transformative discussions and exclusive case studies with industry giants like Sanofi, Merck and Co, Sana Biotechnology, and Capstan Therapeutics. Uniting C-Level Executives, Researchers, and Directors, this event is the only industry-led forum focused on cellular mechanisms to enable targeted intracellular drug delivery. Addressing challenges in compartmentalization and endosomal escape, it aims to optimize therapeutic efficacy and minimize toxicity.

Join us in March 2024 to delve into the forefront of intracellular targeting, where innovation meets expertise to propel your drug pipelines toward unprecedented success.


URLs:
Website: https://go.evvnt.com/2095303-0?pid=10018
Tickets: https://go.evvnt.com/2095303-2?pid=10018
Brochure: https://go.evvnt.com/2095303-3?pid=10018

Prices:
Academic Pricing - Conference + Workshop Day: USD 4197.00,
Academic Pricing - Conference Only: USD 2999.00,
Drug Developer Pricing - Conference + Workshop Day: USD 5097.00,
Drug Developer Pricing - Conference Only: USD 3699.00,
Service Provider Pricing - Conference + Workshop Day: USD 3597.00,
Service Provider Pricing - Conference Only: USD 2599.00

Speakers: Marie McAvoy, Chief Scientific Officer, NanoSyrinx, Shraddha Sharma, Head of In Vitro Biology and Mechanism of Action, Sanofi, Jagesh Shah, Vice President of Gene Therapy and Technologies, Sana Biotechnology, Stephen Kasper, Associate Principal Scientist, Merck and Co, Aric Frantz, Senior Director Pharmacology and Toxicology, Capstan Therapeutics, Christopher Locher, Chief Executive Officer, Versatope Therapeutics, Antonietta Impagliazzo, Director of Future Technologies, Genmab, David Guay, Vice President Innovation and Technology, Feldan Therapeutics, James Ferguson, Chief Medical Officer, Matinas BioPharma, Rajesh Shukla, Senior Medical Director, SSI Strategy, Kyle Trudeau, Senior Director, Gene Therapy Research, Sana Biotechnology, Ravit Uzan, Project Manager, Biond Biologics, Paul Lawrence, Executive Director of Research and Discovery, Biocogent, Kalina Paunovska, Co-founder, Nava Therapeutics, Roman Melnyk, Associate Professor and Senior Scientist, SickKids Hospital, Gary Piazza, Department Head, Drug Discovery and Development, Auburn University, Jean-Phillipe, Pellois Professor, Texas A and M University